BRIEF-Solid Biosciences Reports Positive Initial Clinical Data from SGT-003
ReutersFeb 18, 2025 11:59 AM
Feb 18 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES INC: SGT-003 HAS BEEN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED
SOLID BIOSCIENCES INC - AVERAGE MICRODYSTROPHIN EXPRESSION OF 110% OBSERVED IN PHASE 1/2 TRIAL OF SGT-003
SOLID BIOSCIENCES - PLANS TO REQUEST FDA MEETING FOR ACCELERATED APPROVAL PATHWAY IN MID-2025 FOR SGT-003
Source text: ID:nGNX47H0x5
Further company coverage: SLDB.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Global Crypto Treasury Boom: Which Companies and Tokens Are Becoming Investor Favorites?
A Crypto Treasury refers to a company allocating idle or raised capital to purchase cryptocurrencies, integrating them into its balance sheet as reserve assets or yield-generating tools.TradingKey
Wed, Jul 30
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
